Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Six simple questions contra the delay

Felix C. Ringshausen, Tobias Welte, Albert Nienhaus
European Respiratory Journal 2014 43: 10-11; DOI: 10.1183/09031936.00202813
Felix C. Ringshausen
1Dept of Respiratory Medicine, Hannover Medical School, Hannover
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Ringshausen.Felix@mh-hannover.de
Tobias Welte
1Dept of Respiratory Medicine, Hannover Medical School, Hannover
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Nienhaus
2Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

During the past decades, the incidence of tuberculosis (TB) has steadily declined in most west European countries, and many physicians will no longer encounter TB in their patients. Along with the declining practical experience of physicians, the chance for delay in diagnosing TB increases. An delayed diagnosis of TB index cases is the most important risk factor for the nosocomial transmission of Mycobacterium tuberculosis (MTB) [1], as numerous unprotected contacts among healthcare workers and inpatients may result before the diagnosis of TB is established and respiratory isolation is applied [2, 3]. The clean-up after such a mishap can be complicated and time-consuming, as the individuals concerned need to be identified and contacted. Patients might have been already discharged, or healthcare workers may not be aware of exposure to a TB index case for days or even weeks [4]. However, the difficulty is not over, even when the respective contacts have been identified. As there is no perfect test for the diagnosis of TB infection, the question arises of which test should be used and who should be tested with this assay in order to obtain optimal results. Only close contacts should be tested in order to improve the positive predictive value of the contact screening regardless of the test used. But what is a close contact in a hospital setting? Cumulative exposure to a smear-positive index case for 8 h or more is proposed as an orientation. However, this is merely an inspired guess. In comparison to the tuberculin skin test, the emergence of interferon-γ release assays (IGRAs) has facilitated screening after unprotected TB exposure, as there is no booster phenomenon after repeat testing, no need for a second appointment for test reading and no influence of bacillus Calmette–Guérin vaccination on subsequent test results. However, even with IGRAs, many questions remain unanswered. IGRAs are not able to distinguish remote from recent infection and their ability to predict progression to active disease appears to be limited so far. While progression rates of up to 14% have been reported for close contacts with a positive IGRA result [5, 6], two recent systematic reviews and meta-analyses indicate considerably lower progression risks [7, 8]. Therefore, even after a positive IGRA is observed, the question remains regarding what to do next. Of course, active TB needs to be excluded by chest radiograph. But should we propose preventive chemotherapy to all contacts with a positive IGRA result, well knowing that most of these subjects will never develop active TB anyway?

When a patient with community-acquired pneumonia (CAP) is admitted to the hospital, MTB could almost always be the causative pathogen. However, administering an IGRA for all CAP patients would be a waste of time and money, as current IGRAs are not able to distinguish active TB from latent TB infection. Moreover, the sensitivity of IGRAs may be compromised by the immunological status of the patient. Thus, a negative IGRA does not rule out active TB. Furthermore, active TB might be suspected in far too many contacts in populations with a high prevalence of (remote) latent TB infection and precious time may be lost while sputum results are awaited.

There is a simple and very basic approach to solving this dilemma: asking the right questions! As presented in the large cohort study by Cavallazzi et al. [9] in this issue of the European Respiratory Journal, there are six simple, though crucial, questions for suspecting active TB in patients admitted to the hospital with CAP. These six questions were derived from a set of 22 questions which are known to provide evidence for the diagnosis of TB [10]. However, while 22 questions are hard to remember and take longer to pose, these few simple questions are, besides being more accurate according to the present study [9], considerably easier to remember; as a result, they can even be applied as a bedside tool for predicting the risk of TB in hospitalised patients with CAP in the setting of a busy emergency department with all its time constraints and distractors. Unsurprisingly, weight loss, night sweats, haemoptysis, exposure to MTB and younger age (<65 years) are among these questions. As a result, compared to the original Centers of Disease Control and Prevention score, a significantly improved TB risk assessment was achieved with a subset of risk factors, along with the presence of upper lobe infiltrates.

As respiratory isolation is an effective intervention to prevent the nosocomial transmission of TB and to contribute to TB control [11], the Community-Acquired Pneumonia Organization (CAPO) TB risk score has the potential to contribute to optimal patient care and to facilitate the reasonable allocation of healthcare resources by simplifying and improving TB risk assessment of hospitalised patients with CAP. In this regard, the implementation of the CAPO TB risk score may reduce the delay of identifying potential TB index cases in order to prevent nosocomial transmission to healthcare workers and other patients. Moreover, it may improve the prognosis of TB patients due to timely initiation of adequate treatment [12] and, in addition, guide the choice of empirical antibiotic treatment with regard to the yield of diagnostic tests for MTB [13]. However, it should be noted that atypical clinical and radiological presentations frequently occur among elderly and immunocompromised patients [14].

Future approaches to further improve the informative value of the CAPO TB risk score could encompass the inclusion of the duration of symptoms [15] and the addition of a biomarker different from the MTB-specific interferon-γ response, e.g. C-reactive protein or procalcitonin, which are expected to be low in subjects with CAP due to MTB [16].

As mentioned by the authors, their results need prospective validation in different well-defined clinical settings, particularly given the heterogeneous epidemiology of TB among the 33 contributing countries across Africa, Asia, Australia, Europe, Latin America and USA/Canada, where, in addition, empirical treatment strategies of CAP may differ significantly according to the prevalence of penicillin-resistant pneumococci, the predominant pathogen in CAP, and other multidrug-resistant pathogens [17].

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

  • Received November 19, 2013.
  • Accepted November 20, 2013.
  • ©ERS 2014

References

  1. ↵
    1. de Vries G,
    2. Sebek MM,
    3. Lambregts-van Weezenbeek CS
    . Healthcare workers with tuberculosis infected during work. Eur Respir J 2006; 28: 1216–1221.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Greenaway C,
    2. Menzies D,
    3. Fanning A,
    4. et al
    . Delay in diagnosis among hospitalized patients with active tuberculosis–predictors and outcomes. Am J Respir Crit Care Med 2002; 165: 927–933.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Nienhaus A,
    2. Schablon A,
    3. Ringshausen FC,
    4. et al
    . TB as an occupational disease. Eur Respir Monogr 2012; 58: 219–229.
    OpenUrl
  4. ↵
    1. Ringshausen FC,
    2. Schlosser S,
    3. Nienhaus A,
    4. et al
    . In-hospital contact investigation among health care workers after exposure to smear-negative tuberculosis. J Occup Med Toxicol 2009; 4: 11.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Diel R,
    2. Loddenkemper R,
    3. Niemann S,
    4. et al
    . Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011; 183: 88–95.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Haldar P,
    2. Thuraisingam H,
    3. Patel H,
    4. et al
    . Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 2013; 68: 240–246.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Diel R,
    2. Loddenkemper R,
    3. Nienhaus A
    . Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63–75.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Rangaka MX,
    2. Wilkinson KA,
    3. Glynn JR,
    4. et al
    . Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45–55.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Cavallazzi R,
    2. Wiemken T,
    3. Christensen D,
    4. et al
    . Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. Eur Respir J 2014; 43: 178–184.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54: 1–141.
    OpenUrlPubMed
  11. ↵
    1. Raviglione M,
    2. Marais B,
    3. Floyd K,
    4. et al
    . Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902–1913.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Sreeramareddy CT,
    2. Panduru KV,
    3. Menten J,
    4. et al
    . Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis 2009; 9: 91.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dooley KE,
    2. Golub J,
    3. Goes FS,
    4. et al
    . Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607–1612.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Geng E,
    2. Kreiswirth B,
    3. Burzynski J,
    4. et al
    . Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 2005; 293: 2740–2745.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Liam CK,
    2. Pang YK,
    3. Poosparajah S
    . Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology 2006; 11: 786–792.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Ugajin M,
    2. Miwa S,
    3. Shirai M,
    4. et al
    . Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011; 37: 371–375.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Welte T,
    2. Kohnlein T
    . Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009; 30: 127–135.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 43 Issue 1 Table of Contents
European Respiratory Journal: 43 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Six simple questions contra the delay
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Six simple questions contra the delay
Felix C. Ringshausen, Tobias Welte, Albert Nienhaus
European Respiratory Journal Jan 2014, 43 (1) 10-11; DOI: 10.1183/09031936.00202813

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Six simple questions contra the delay
Felix C. Ringshausen, Tobias Welte, Albert Nienhaus
European Respiratory Journal Jan 2014, 43 (1) 10-11; DOI: 10.1183/09031936.00202813
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Commemorating World Tuberculosis Day 2022
  • Is low level of vitamin D a marker of poor health or its cause?
  • Are ICS increasing the “load” for some patients with COPD?
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society